Scholars Central

Mini reviewPublished 30 Sep 2023

Alterations in Eosinophil Cationic Protein in Asthma and CRSwNP Participants Receiving Dupilumab

Authors: Matsumoto Yasushi

Journal of Biomedical and Pharmaceutical Sciences

Volume 6 · Issue 5 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are chronic inflammatory diseases that affect the respiratory and nasal passages, respectively. Both conditions are often characterized by elevated levels of eosinophil, a type of white blood cell that plays a crucial role in the immune response. Eosinophilic inflammation is a key feature of these diseases and is associated with a range of symptoms and complications. Dupilumab is a monoclonal antibody that targets the interleukin-4 receptor alpha subunit, inhibiting the signaling of both interleukin-4 (IL-4) and interleukin-13 (IL-13). Dupilumab has demonstrated remarkable efficacy in treating asthma and CRSwNP, significantly reducing symptoms and improving the quality of life for many patients. This success can be attributed to its ability to reduce eosinophilic inflammation, which leads to alterations in various biomarkers, including Eosinophil Cationic Protein (ECP).

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Biomedical and Pharmaceutical Sciences.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Biomedical and Pharmaceutical Sciences
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Matsumoto Yasushi”